These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32790556)

  • 21. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
    Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of neuromodulation in patients with neurogenic overactive bladder.
    Lay AH; Das AK
    Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Invasive neurostimulation in neuro-urology: state of the art].
    Kurze I; Böthig R; van Ophoven A
    Aktuelle Urol; 2024 Aug; 55(4):351-364. PubMed ID: 38631373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence.
    Ferreira R; Alwashmi E; Otis-Chapados S; Bhojani N; Zorn KC; Chughtai B; Elterman DS
    Can J Urol; 2024 Aug; 31(4):11943-11949. PubMed ID: 39217518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
    Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
    J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
    Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sacral Neuromodulation in Patients With Neurogenic Lower Urinary Tract Dysfunction: A Multicenter Retrospective Study From China.
    Masood I; Chen Q; Li J; Xu Z; Ying X; Wang Y; Chen G; Liao L
    Neuromodulation; 2021 Oct; 24(7):1278-1283. PubMed ID: 33908130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
    Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
    Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: a multicenter retrospective cohort study from China.
    Meng L; Yan Z; Wang X; Zhang Y; Zhu Z; Zhu W; Ling Q; Sun X; Gu Y; Lv J; Li Y
    Int J Surg; 2024 Jun; 110(6):3536-3542. PubMed ID: 38445489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacral Neuromodulation for Genitourinary Problems.
    Banakhar M; Hassouna M
    Prog Neurol Surg; 2015; 29():192-9. PubMed ID: 26394134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.